Can-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer

MT Newswires Live

2024/11/11

Can-Fite BioPharma (CANF) said Monday that the first patient has been dosed in its phase 2a trial of Namodenoson in patients with advanced pancreatic adenocarcinoma.

The company said it targets to enroll about 20 evaluable patients in the trial.

The study's primary objective is to characterize Namodenoson's safety profile, while the secondary objective is to evaluate clinical activity using overall response rate, overall survival, and progression-free survival, among others, Can-Fite added.

Price: 2.7500, Change: -0.07, Percent Change: -2.48

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2482783992"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2482783992\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2482783992?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-11 20:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2482783992","market":"fut","top_or_hot":-1,"title":"Can-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer","media":"MT Newswires Live","content":"<html><body><p> Can-Fite BioPharma (CANF) said Monday that the first patient has been dosed in its phase 2a trial of Namodenoson in patients with advanced pancreatic adenocarcinoma.</p><p>The company said it targets to enroll about 20 evaluable patients in the trial.</p><p>The study's primary objective is to characterize Namodenoson's safety profile, while the secondary objective is to evaluate clinical activity using overall response rate, overall survival, and progression-free survival, among others, Can-Fite added.</p><p>Price: 2.7500, Change: -0.07, Percent Change: -2.48</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan-Fite BioPharma Doses First Patient in Namodenoson Phase 2a Trial in Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-11 20:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Can-Fite BioPharma (CANF) said Monday that the first patient has been dosed in its phase 2a trial of Namodenoson in patients with advanced pancreatic adenocarcinoma.</p><p>The company said it targets to enroll about 20 evaluable patients in the trial.</p><p>The study's primary objective is to characterize Namodenoson's safety profile, while the secondary objective is to evaluate clinical activity using overall response rate, overall survival, and progression-free survival, among others, Can-Fite added.</p><p>Price: 2.7500, Change: -0.07, Percent Change: -2.48</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CANF","symbol_name":"Can-Fite Biopharma Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2482783992","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2482783992","pubTimestamp":1731328388,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Can-Fite BioPharma  said Monday that the first patient has been dosed in its phase 2a trial of Namodenoson in patients with advanced pancreatic adenocarcinoma.The company said it targets to enroll about 20 evaluable patients in the trial.The study's primary objective is to characterize Namodenoson's safety profile, while the secondary objective is to evaluate clinical activity using overall response rate, overall survival, and progression-free survival, among others, Can-Fite added.Price: 2.7500, Change: -0.07, Percent Change: -2.48","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CANF":"Can-Fite Biopharma Ltd","BK4139":"生物科技"},"translate_title":"Can-Fite BioPharma为胰腺癌namodenoson 2a期试验中的首例患者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CANF":0.9},"content_text":"Can-Fite BioPharma (CANF) said Monday that the first patient has been dosed in its phase 2a trial of Namodenoson in patients with advanced pancreatic adenocarcinoma.The company said it targets to enroll about 20 evaluable patients in the trial.The study's primary objective is to characterize Namodenoson's safety profile, while the secondary objective is to evaluate clinical activity using overall response rate, overall survival, and progression-free survival, among others, Can-Fite added.Price: 2.7500, Change: -0.07, Percent Change: -2.48","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}